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metabolites measured using nuclear magnetic
resonance spectroscopy in a UK population
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Abstract
Background: Nuclear magnetic resonance (NMR) spectroscopy allows triglycerides to be subclassified into 14 different
classes based on particle size and lipid content. We recently showed that these subfractions have differential associations
with cardiovascular disease events. Here we report the distributions and define reference interval ranges for 14
triglyceride-containing lipoprotein subfraction metabolites.
Methods: Lipoprotein subfractions using the Nightingale NMR platform were measured in 9073 participants from four
cohort studies contributing to the UCL-Edinburgh-Bristol consortium. The distribution of each metabolite was
assessed, and reference interval ranges were calculated for a disease-free population, by sex and age group (<55,
55–65, >65 years), and in a subgroup population of participants with cardiovascular disease or type 2 diabetes. We
also determined the distribution across body mass index and smoking status.
Results: The largest reference interval range was observed in the medium very-low density lipoprotein subclass (2.5th
97.5th percentile; 0.08 to 0.68mmol/L). The reference intervals were comparable among male and female participants,
with the exception of triglyceride in high-density lipoprotein. Triglyceride subfraction concentrations in very-low density
lipoprotein, intermediate-density lipoprotein, low-density lipoprotein and high-density lipoprotein subclasses increased
with increasing age and increasing body mass index. Triglyceride subfraction concentrations were significantly higher in
ever smokers compared to never smokers, among those with clinical chemistry measured total triglyceride greater than
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1.7mmol/L, and in those with cardiovascular disease, and type 2 diabetes as compared to disease-free subjects.
Conclusion: This is the first study to establish reference interval ranges for 14 triglyceride-containing lipoprotein
subfractions in samples from the general population measured using the nuclear magnetic resonance platform. The utility
of nuclear magnetic resonance lipid measures may lead to greater insights for the role of triglyceride in cardiovascular
disease, emphasizing the importance of appropriate reference interval ranges for future clinical decision making.
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Introduction
Risk factors for atherosclerotic disease include elevated
total cholesterol, LDL-cholesterol (LDL-C) and trigly-
cerides (TGs), and are used in disease risk assessment in
clinical care.1 Elevated TGs are common among people
with metabolic syndrome, obesity and type 2 diabetes
(T2DM),2,3 and are associated with an increased risk of
cardiovascular disease (CVD).4 Population-based ref-
erence intervals are used as a tool to define thresholds
for clinical decisions. For example, clinical measure-
ment of LDL-C for CVD risk assessment, which
together with other measurements such as body mass
index (BMI) or systolic blood pressure (SBP) can help
to determine if lipid-lowering is indicated.5
The high-throughput proton (1H) serum nuclear
magnetic resonance (NMR) metabolomics platform
developed by Nightingale provides quantitative infor-
mation on lipoprotein particle size and lipid content
representing multiple metabolic pathways.6–8 NMR
measures of lipoproteins are increasingly used in epide-
miological and genetic studies, and may provide better
insights into biological processes when compared to
clinical chemistry measures of TG, which represent
the sum of all plasma TG.9
The Nightingale NMR metabolomics approach has
been used in two recent prospective cohort studies that
found evidence to suggest a differential association of
total serum TG and TG subfractions with coronary
heart disease (CHD).10,11 For example, total serum TG
association with CHD was OR 1.19 (95% CI 1.10 to
1.28), TG in the VLDL subfractions was associated
with CHD in the range of OR 1.12 to 1.22, whereas
TG in the LDL sub-fractions conveyed a relatively
lower risk (OR in the range 1.13 to 1.17).11 The different
associations of the 14 TG-subfractions with CHD high-
light the need to extend the standard lipid reference inter-
vals to include lipid lipoprotein subfractions.
In the present study, we aim to define reference
intervals for 14 TG-containing lipoprotein subfraction
metabolites (TG subfractions) using data from multiple




We sourced data from the UCLEB consortium,
including NMR metabolite measures in 9073
participants from four cohort studies: The British
Regional Heart Study (BRHS), including male aged
60–79 at assessment in 1998–2000, the Whitehall II
Study (WHII), including UK government workers
aged 45–69 years at assessment in 1997 to 1999, the
Southall and Brent Revisited Study (SABRE), a tri-
ethnic study including British men and women from
European (SABRE1), South Asian (SABRE2) and
African Caribbean (SABRE3) descent, and the
Caerphilly Prospective Study (CAPS), including male
registered in general practice aged 55–69 at assessment
in 1989–1993. The design and data collection for the
UCLEB Consortium of longitudinal population studies
have been described previously.12 Age (years), sex
(male/female), smoking (ever/never), BMI, CHD,
stroke and T2DM variables were collected at the time
of NMR blood sample measurement.
Metabolite quantification
Using Nightingale NMR metabolomics platform,8
high-throughput metabolite quantification of 14 TG-
containing lipoprotein subfractions (mmol/L) was
ascertained in fasting and non-fasting serum samples
in all contributing studies. To ensure long-term
sample integrity, blood samples were stored and trans-
ported at 80C across all contributing UCLEB
studies until NMR quantification in 2014. NMR
metabolomics platform has been extensively used in
epidemiology and genetics studies,13–15 and its
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application reviewed and described in detail
elsewhere.6,16
Statistical analysis
We removed individuals based on any event of CHD,
stroke or T2DM to include a healthy, ‘disease free’
population. We first assessed the study-specific distri-
bution of each 14 TG subfraction and then pooled indi-
vidual participant data form all four cohorts into one
dataset. Reference intervals were based on the 2.5th
and 97.5th percentiles stratified by age and sex. Age
group bands were calculated as <55 years, 55–
65 years and >65 years. The influence of fasting, age,
smoking and BMI on the subfraction distributions was
assessed statistically and graphically using ‘generalised
linear model’ (GAM) curves, Kolmogorov–Smirnov
(KS) test and using box plots. Reference intervals
were additionally calculated in the following groups;
(1) participants with CVD (defined as occurrence of
either CHD or stroke), (2) participants with T2DM,
(3) participants with clinical chemistry total TG great-
er, or less than 1.7mmol/L and (4) TG measured in the
fasting and non-fasting state.
Results
A total of 9073 individuals were included in the main
healthy, free of CVD and T2DM study sample, of
which 5574 (62.8%) were male (median age
61.7 years, IQR 52.0, 67.6) who had median BMI of
26.0 (IQR 23.9, 28.4) kg/m2 and 3027 (54.2%) were
current or ex-smokers (i.e. ever smokers). Female par-
ticipants had a median age of 53.9 (IQR 49.9, 59.9), a
BMI of 25.6 (23.6, 27.8) kg/m2 and 431 (13.0%) were
ever smokers. Description of study population and
median concentration of 14 subfractions is shown in
Table 1.
We compared the sum of TG in the 14 subfractions
to clinical chemistry measured total TG and found an
increase of 0.34mmol/L of NMR measured total TG
for every 1mmol/L increase in clinical chemistry mea-
sured total TG (Supplemental Figure 1). The overall
study population distribution for the 14 TG subfrac-
tions was comparable across contributing studies,
showed agreement between ethnicities in the Southall
and Brent Revisited Study cohort (Supplemental
Figure 2) and an overlap of TG measured in the fasting
and non-fasting state (Supplemental Figure 3). Of the
14 TG subfractions, 12 had a skewed right tailed dis-
tribution, and two (medium and small HDL) had a
more symmetrical distribution.
The reference intervals (2.5th–97.5th) percentile for
14 TG subfractions are shown in Table 2 and graphi-
cally in Figure 1. Wide reference intervals were
observed in the VLDL subclass, for example the refer-
ence interval for TG in medium VLDL and small
VLDL was 0.08–0.67mmol/L and 0.10–0.46mmol/L,
respectively. A smaller reference interval range was
observed for TG in IDL, LDL and HDL subclass sub-
fractions, for example, the reference interval range for
TG in large HDL was 0.01–0.05mmol/L.
Subgroup reference interval ranges
Age and sex stratified reference interval ranges for 14
TG metabolites are presented in Supplemental Table 2.
Reference interval ranges (2.5th–97.5th percentile) were
comparable between male and female participants
across metabolites. For example, among male partici-
pants aged <55 years, the large VLDL reference inter-
val was in the range of 0.01–0.24mmol/L, and for
female participants of the same age band, the reference
interval range was 0.02–0.03mmol/L.
Figure 2 shows GAM curves and density distribu-
tion for the sum of VLDL, IDL, LDL and HDL sub-
class subfractions for age and BMI, and box plot for
TG distribution by smoking status. Among male par-
ticipants, TG concentration increased with age, with
the most prominent age differences observed in the
HDL subclass (Figure 2, left panel). By comparison,
TG concentration differences were not as noticeable
for female participants for whom concentrations
were comparable for the VLDL, IDL, LDL and
HDL subclasses by age. For both men and women,
TG subfraction concentration increased with increas-
ing BMI for the VLDL, IDL, LDL and HDL sub-
classes. Ever smokers had higher mean TG
subfraction concentrations across all subclasses as
compared to never smokers.
In the disease subgroups that were removed from all
previous analyses reported above, the reference interval
ranges for 14 subfractions were comparable between
those with CVD (N¼ 2719 and those with T2DM
(N¼ 1325). In general, the largest variation in reference
interval range across the subfractions between these
subgroups was observed in the VLDL subclass
(Supplemental Table 3). For example, the 2.5th to
97.5th reference interval range for TG in medium
VLDL in CVD: 0.09, 0.79mmol/L and in T2DM:
0.08, 0.84mmol/L.
The reference interval ranges across 14 TG subfrac-
tions were comparable in TG measured in the fasting
and non-fasting state and were higher in the group with
clinical chemistry measured total TG greater than
1.7mmol/L as compared to less than 1.7mmol/L, see
(Supplemental Table 3).
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Discussion
This study provides reference interval ranges for TG in
14 lipoprotein subfraction metabolites as measured by
NMR spectroscopy based on a sample of UK adults.
There was agreement in the distribution of TG subfrac-
tion concentrations between ethnicities. TG concentra-
tions for male and female participants increase with
increasing age and BMI, are higher among ever
Table 1. Description of study sample.
Male (n¼ 5574) Female (n¼ 3299)
Age, years 61.7 (52.0, 67.6) 53.9 (49.9, 59.9)
BMI, kg/m2 26.0 (23.9, 28.4) 25.6 (23.6, 27.8)
Smoking, ever 3027/5574 (54.2) 431/3299 (13.0)
Triglyceride subfraction (mmol/L)
Extremely large VLDL 0.02 (0.01–0.03) 0.02 (0.01–0.02)
Very large VLDL 0.03 (0.01–0.05) 0.02 (0.01–0.04)
Large VLDL 0.10 (0.06–0.18) 0.09 (0.05–0.16)
Medium VLDL 0.23 (0.16–0.35) 0.24 (0.16–0.34)
Small VLDL 0.22 (0.18–0.29) 0.23 (0.17–0.30)
Very small VLDL 0.11 (0.09–0.13) 0.12 (0.09–0.14)
IDL 0.12 (0.10–0.14) 0.12 (0.10–0.15)
Large LDL 0.10 (0.08–0.12) 0.10 (0.09–0.12)
Medium LDL 0.05 (0.04–0.06) 0.05 (0.04–0.05)
Small LDL 0.03 (0.02–0.04) 0.03 (0.02–0.04)
Very large HDL 0.01 (0.01–0.02) 0.01 (0.01–0.02)
Large HDL 0.03 (0.02–0.04) 0.02 (0.02–0.03)
Medium HDL 0.05 (0.04–0.06) 0.05 (0.04–0.06)
Small HDL 0.05 (0.04–0.06) 0.04 (0.04–0.05)
Note: Values are median (IQR) or %.
VLDL: very-low density lipoprotein; IDL: intermediate-density lipoprotein; LDL: low-density lipoprotein; HDL: high-density lipoprotein
Table 2. Reference interval range of 14 TG-subfractions
(n¼ 9073).
TG subfraction (mmol/L) 2.50% 97.50%
Extremely large VLDL 0.01 0.06
Very large VLDL <0.01 0.13
Large VLDL 0.01 0.42
Medium VLDL 0.08 0.67
Small VLDL 0.10 0.46
Very small VLDL 0.06 0.20
IDL 0.07 0.20
Large LDL 0.06 0.17
Medium LDL 0.02 0.08
Small LDL 0.01 0.05
Very large HDL <0.01 0.03
Large HDL 0.01 0.05
Medium HDL 0.02 0.08
Small HDL 0.03 0.08
VLDL: very-low density lipoprotein; IDL: intermediate-density lipopro-
tein; LDL: low-density lipoprotein; HDL: high-density lipoprotein; TG:
triglyceride.
Figure 1. Reference interval range for 14 triglyceride subfrac-
tions (median, 2.5th, 97.5th) percentiles.
Note. Please refer to the online version of the article to view the
figure in colour.
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smokers and in those with CVD and T2DM as com-
pared to disease-free subjects, and in individuals with
total TG concentrations greater than 1.7mmol/L.
Lipid reference interval ranges are derived using
clinical chemistry measurement of blood samples
from a reference population and are necessary to
enable clinicians to apply analytical data in healthcare
delivery. For example, clinical chemistry estimates of
LDL-C are measured in individuals and evaluated
against an interval range to inform lifestyle or thera-
peutic intervention for CHD prevention. The role of
TG in CHD risk is less clear. Meta-analysis from pro-
spective observational studies has demonstrated higher
concentrations of clinical chemistry measured total TG
are associated with higher risk of CHD, but effect esti-
mates attenuate to the null after adjustment for HDL-
C.17 On the other hand, Mendelian randomization
studies support a potential causal association for
TG.18 The association of the major blood lipid frac-
tions (LDL-C, TG and HDL-C) with CHD is seen
across the whole of the concentration range, with no
threshold value and we expect the same to be true of
TG-containing lipoprotein subfractions. The reference
ranges we report should not therefore be taken to imply
that individuals whose measurements lie within these
ranges are free of CHD risk. Rather we simply report
the observed values in general UK populations.
NMR methodology offers the potential for more
granular quantification of TG in different lipoproteins
that would otherwise be unavailable using conventional
approaches, enabling a more detailed investigation of
TG-containing lipoprotein subfractions in relation to
CHD risk and prognosis. Evidence from studies using
this approach suggest CHD risk may be divergent
depending on the type of lipoprotein subfraction.
Two recent studies report observations of TG in
Figure 2. Distribution of TG concentration in VLDL, IDL, LDL and HDL subclass by age (left panel), body mass index (centre panel)
and smoking status (right panel). N.b. Slope indicates a GAM estimate with 95% confidence interval. Tile colours represent the
number of observations, with purple coloured tiles indicating a higher density. Smoking distribution (right panel) is based on data from
BRHS, SABRE and WHII studies. All were significant at P value threshold for <0.00. VLDL: very-low density lipoprotein; IDL:
intermediate-density lipoprotein; LDL: low-density lipoprotein; HDL: high-density lipoprotein; BRHS: British Regional Heart Study;
SABRE: the Southall and Brent Revisited Study; WHII: the Whitehall II Study.
Note. Please refer to the online version of the article to view the figure in colour.
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VLDL subfractions may be more atherogenic and asso-
ciated with a higher risk of CHD compared to TG in
the IDL, LDL and HDL subclass subfractions.10,11
This study evaluates the concentration distribution
and range of TG in 14 subfractions and includes data
from multiple UK population cohorts and from male
and female participants from a range of age groups and
ethnicities including European, South Asian and
African-Caribbean ancestry. We compare total TG
measured using clinical chemistry and the sum of
NMR TG across the 14 subfractions. Discrepancies
between clinical chemistry methods and NMR mea-
sured total TG have been reported previously.10,17 In
one such study, Balling et al.17 suggest differences in
analytical calibration from measurement of TGs
between the two methods may lead to measurement
differences, with NMR quantification deemed as the
more accurate method.18 TG concentrations are vari-
able and, in addition to age, sex and ethnicity, can
depend on factors such as food intake, fasting/non-
fasting state, CVD and metabolic disorders such as
T2DM.19 Due to the relatively large sample sizes avail-
able, we observed a significant difference between the
fasting and non-fasting distribution of subfractions.
This significant difference did not prove relevant for
determining the reference interval ranges, which were
comparable to two decimal points. Moreover, it is pos-
tulated that the non-fasting state predominates the 24-
h cycle due to varying food intake patterns, and mean
changes of þ0.3mmol/L from baseline TG measures
do not translate to clinically significant differences.
Higher TG concentrations are observed in postmeno-
pausal vs. premenopausal female.20 We report compa-
rable TG concentrations across age groups; however, it
is possible that a greater difference in TG concentra-
tion may be observed in a larger sample of women aged
>65 than are included here. Due to the small numbers
of current smokers in the available data across the con-
tributing cohorts, we stratified by ever and never smok-
ing status, instead of the more informative ‘never’, ‘ex
and ‘current’ smokers. We exclude participants with
current CVD or T2DM in the main analyses; however,
it is possible that the TG concentrations in the study
population were altered by other diseases or by lipid-
lowering medication, which we were not able to
account for in this study. It is likely TG monitoring
is likely to occur in individuals at risk of, or with cur-
rent CVD. Therefore, we provide additional reference
intervals in participants with CVD and T2D.
We establish reference interval ranges of 14 TG-
containing lipoprotein subfractions for male and
female by age, BMI, smoking status, CVD, T2DM
and stratified by clinical chemistry measured total TG
and fasting status for population-based cohorts from
the UK population. Further studies would be needed
to assess if the reference intervals presented here could
be extended to a non-UK population and if the risks
associated with the reference intervals identify a thresh-
old within these ranges to inform CVD risk in a clinical
setting. By doing so, the reference interval ranges may
help to set realistic targets and guide research interests,
contributing to the development of effective targeted
TG-lowering therapies, aimed at, for example VLDL
subfractions which may be the most atherogenic.10
NMR lipoprotein particle number and size have been
assessed in relation to CHD; however, this study spe-
cifically presents reference range intervals for TG
within the 14 subfractions.21 Further investigations
would be needed to compare subfraction lipid compo-
sition, particle number concentration and size.
Metabolomics is becoming integrated with genomics
to contribute to a better understanding of disease aeti-
ologies and disease risk.22 It is likely that quantitative
metabolomics will be incorporated into large biobanks,
which would extend the relevance of sample collection
and encourage the life-long assessment of metabolic
health.6 TG subfraction reference interval ranges may
help complement current routine clinical chemistry
measures of lipids and become an integral tool in tar-
geted patient management and improved disease risk
prediction and prevention.
Conclusion
This study is the first to establish reference interval
ranges for 14 TG-containing lipoprotein subfraction
metabolites, measured using the Nightingale NMR
platform for men and women in a UK population.
NMR measures of lipoproteins may provide insights
into biological processes compared to clinical chemistry
measures of TG and lead to greater insights for the role
of TG in CVD, emphasizing the importance of appro-
priate reference interval ranges for future clinical deci-
sion making.
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